Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
about
A Pilot Study of Mifepristone in Combat-Related PTSDEffect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulationCharacterization of a molecular switch system that regulates gene expression in mammalian cells through a small molecule.The state-of-the-art of emergency contraception with the cutting edge drug.Regulated production of proteins from muscle using gene transfer: potential therapeutic applications.Greater glucocorticoid receptor activation in hippocampus of aged rats sensitizes microglia.Gene therapy progress and prospects: transcription regulatory systems.The potential of mifepristone (RU-486) as an emergency contraceptive drug.Development and Evaluation of Novel Self-Nanoemulsifying Drug Delivery Systems Based on a Homolipid from Capra hircus and Its Admixtures with Melon Oil for the Delivery of IndomethacinAn engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice.Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200Acute stress is detrimental to heart regeneration in zebrafishMedical termination of pregnancy in cynomolgus macaques.Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone.Genomic and Nongenomic Effects of Mifepristone at the Cardiovascular Level: A Review.Regulated and constitutive expression of anti-inflammatory cytokines by nontransforming herpesvirus saimiri vectors.Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses.Frequent low-dose misoprostol for termination of second-trimester pregnancy.Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion.Evaluation of dika wax-soybean oil-based artesunate-loaded lipospheres: in vitro-in vivo correlation studies.Effect of ulipristal acetate and mifepristone at emergency contraception dose on the embryo-endometrial attachment using an in vitro human trophoblastic spheroid and endometrial cell co-culture model.Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.Assessment of effects of mifepristone administration to lactating mice on the development and fertility of their progeny.
P2860
Q21296643-5A34BB23-2D69-476F-BF62-AF8D40383BBAQ28538130-36BF046A-46E4-4F6D-AD47-27085FB2E140Q33532286-63E72091-E45F-4371-90B6-0CC177B0FB3EQ34631343-95A9C2D0-EDC9-4805-B3C8-9A4A5C86892FQ35093620-EA5CB872-981F-42D5-81D3-09DB72081F3FQ35137555-2EB0956D-8141-45C7-8581-23F3CA368D2DQ35676294-EAD554C3-6A63-4EC1-9989-865DD33F3A37Q36068813-85FE577A-4E19-4D04-9178-31A31FEA6E0EQ36112240-B0477F96-52A8-41DF-9CA4-8C5C17418BCEQ36328854-381C425A-590E-4A69-81B3-70BB7C8A37F6Q36336980-F4C65D04-B04E-44AA-A5E1-015470CCC21CQ36766532-22569667-AB6F-4655-9479-39580ABE529CQ36777695-704A876E-0B16-4786-BBCC-A206EDBBC981Q37587889-7B31665E-7B2F-4C1D-96FB-89B24C6321EFQ38966345-55353DD2-1D7D-4A3B-B400-86F7AE7763D8Q40454852-0654CC3C-67E7-4B66-A604-6C0683C8E721Q42381161-28AB604E-D79F-4989-96B3-41F68A9467A9Q45048214-3244C31F-D5F6-4896-A280-8AC0899F8B68Q46600730-DC91AC73-7C20-4348-99D5-2CDD6F9C3C50Q46933840-61E009B0-2C78-4FBB-A73E-034C02BC44C5Q47221830-DEE7BEFF-E254-4CAC-A5FF-F3D26D2A404FQ50057501-0CD3FA8F-5E44-4BD6-B2DC-5486B1EBB598Q51105899-C0F1568B-28FC-4E78-9C94-64B03EAEFAD4
P2860
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@ast
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@en
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@nl
type
label
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@ast
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@en
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@nl
prefLabel
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@ast
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@en
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@nl
P1476
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
@en
P2093
P304
P356
10.1016/S0301-2115(01)00522-X
P577
2002-03-01T00:00:00Z